Clinical trial
Melanoma Vaccine With Peptides and Leuprolide
NCT00254397 · M.D. Anderson Cancer Center, Other · Completed
Key facts
| NCT number | NCT00254397 |
|---|---|
| Title | Melanoma Vaccine With Peptides and Leuprolide |
| Official title | Study of the Modulatory Activity of an LHRH-Agonist (Leuprolide) on Melanoma Peptide Vaccines as Adjuvant Therapy in Melanoma Patients |
| Lead sponsor | M.D. Anderson Cancer Center, Other |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Melanoma |
| Intervention type | Biological, Drug |
| Interventions | Leuprolide, GP100: 209-217(210M) Peptide, MAGE-3 Peptide |
| Enrollment | 98 |
| Start date | Nov 1, 2005 |
| Primary completion | Oct 1, 2012 |
| Completion | Oct 1, 2012 |
| First posted | Nov 16, 2005 |
| Last update posted | Oct 16, 2019 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: